MESO
NASD Mesoblast Limited Sponsored ADR$14.79 ↑ +0.29 (+1.99%) Trading Up from the previous close of $14.50, and at the day’s high of $14.62
- YTD change
- -18.02%
- vs 20-day SMA
- -6.82%
- vs 200-day SMA
- -7.81%
Price ranges
Price & Performance
+0.13 (+0.90%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 65.3% away from all-time highs of $42.56
- MESO is down 18% since the beginning of the year
- MESO is down 7% over the past 12 months
- MESO is down 19% over the past 1 month
- 3% of all MESO investors are betting against MESO
MESO reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -9.5%.
- Previous minute
- +$0.00
- Last hour
- +$0.29
- Last 5 days
- -2.26%
- vs 8-day SMA
- -2.79%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
